The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Clinical

chronic kidney disease

Renal outcomes and dose considerations.

35 topics 10 solved Group: Clinical

Related in this group: HbA1c · lipid panel · eGFR & renal function · liver enzymes · thyroid function · lipase & amylase · inflammatory markers · micronutrients · blood pressure · heart rate · type 2 diabetes · MASH / hepatic steatosis

35 topics · page 2 of 2

TopicParticipantsRepliesViewsActivity
Renal impairment: what the labelling says about dose
On the subject in the title: Renal impairment: what the labelling says about dose Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference…
OVJPZOFKJB 4 8.9k 19mo
People with a low starting BMI: where the evidence stops
Posting this under the heading it deserves: People with a low starting BMI: where the evidence stops Everything below is what sits behind that. Asking about a population rather than about a person. The…
VFJDSOAWAW+23 27 5.8k 19mo
Type 2 diabetes and the largest part of the evidence base — does this still hold?
Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather…
NANKEML+18 25 1.7k 22mo
[2026 update] People with a low starting BMI: where the evidence stops
People with a low starting BMI: where the evidence stops Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
VBGPKBCRMG+19 23 62k 23mo
Chronic kidney disease and the FLOW result
Posting this under the heading it deserves: Chronic kidney disease and the FLOW result Everything below is what sits behind that. General question, not a request for advice about my own care — I know the…
PAVOFJCN+34 38 33k 23mo